Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation.
OBJECTIVE
To determine the frequency of estrogen receptor alpha and beta and progesterone receptor protein immunohistochemical expression in a large set of non-small cell lung carcinoma (NSCLC) specimens and to compare our results with those for some of the same antibodies that have provided inconsistent results in previously published reports.


METHODS
Using multiple antibodies, we investigated the immunohistochemical expression of estrogen receptors alpha and beta and progesterone receptor in 317 NSCLCs placed in tissue microarrays and correlated their expression with patients' clinicopathologic characteristics and in adenocarcinomas with EGFR mutation status.


RESULTS
Estrogen receptors alpha and beta were detected in the nucleus and cytoplasm of NSCLC cells; however, the frequency of expression (nucleus, 5-36% for alpha and 42-56% for beta; cytoplasm: <1-42% for alpha and 20-98% for beta) varied among the different antibodies tested. Progesterone receptor was expressed in the nuclei of malignant cells in 63% of the tumors. Estrogen receptor alpha nuclear expression significantly correlated with adenocarcinoma histology, female gender, and history of never smoking (P = 0.0048 to <0.0001). In NSCLC, higher cytoplasmic estrogen receptor alpha expression significantly correlated with worse recurrence-free survival (hazard ratio, 1.77; 95% confidence interval, 1.12, 2.82; P = 0.015) in multivariate analysis. In adenocarcinomas, estrogen receptor alpha expression correlated with EGFR mutation (P = 0.0029 to <0.0001). Estrogen receptor beta and progesterone receptor but not estrogen receptor alpha expressed in the normal epithelium adjacent to lung adenocarcinomas.


CONCLUSIONS
Estrogen receptor alpha and beta expression distinguishes a subset of NSCLC that has defined clinicopathologic and genetic features. In lung adenocarcinoma, estrogen receptor alpha expression correlates with EGFR mutations.
Raso
Maria G
MG
Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA.
Behrens
Carmen
C
Herynk
Matthew H
MH
Liu
Suyu
S
Prudkin
Ludmila
L
Ozburn
Natalie C
NC
Woods
Denise M
DM
Tang
Ximing
X
Mehran
Reza J
RJ
Moran
Cesar
C
Lee
J Jack
JJ
Wistuba
Ignacio I
II
D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D002467:Cell Nucleus / Q000378:metabolism; D003593:Cytoplasm / Q000378:metabolism; D066246:ErbB Receptors / Q000235:genetics; D047628:Estrogen Receptor alpha / Q000378:metabolism*; D047629:Estrogen Receptor beta / Q000378:metabolism*; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D015999:Multivariate Analysis; D009154:Mutation / Q000235:genetics; D016016:Proportional Hazards Models; D011980:Receptors, Progesterone / Q000378:metabolism*; D012044:Regression Analysis; D046888:Tissue Array Analysis
D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D011980:Receptors, Progesterone; D066246:ErbB Receptors
Cancer Res. 2005 Feb 15;65(4):1598-605
15735050
Br J Cancer. 2001 Apr 20;84(8):1095-8
11308260
Br J Cancer. 2002 Jul 1;87(1):43-8
12085254
Cancer Res. 2005 Dec 15;65(24):11478-85
16357156
Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4130-5
15024130
Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4583-8
17671145
Am J Pathol. 2000 Jan;156(1):29-35
10623650
J Mol Endocrinol. 2000 Feb;24(1):145-55
10657006
Lung Cancer. 2002 Aug;37(2):153-9
12140138
Anticancer Res. 1996 Nov-Dec;16(6B):3803-6
9042261
Mol Cancer Ther. 2007 Oct;6(10):2626-33
17913855
Annu Rev Med. 2008;59:429-42
17716025
Anticancer Res. 2005 Nov-Dec;25(6C):4693-8
16334162
Steroids. 2007 Feb;72(2):135-43
17276470
Lung Cancer. 2009 Apr;64(1):51-9
18701186
Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5813-24
14676101
Trends Endocrinol Metab. 2005 Jul;16(5):222-7
15936211
Clin Cancer Res. 2005 Jul 15;11(14):5084-9
16033821
Chest. 1997 Jun;111(6):1710-7
9187198
Curr Mol Med. 2007 Feb;7(1):3-14
17311529
Lung Cancer. 2008 Jan;59(1):88-94
17905466
Mol Cell Endocrinol. 2002 Feb 25;188(1-2):125-40
11911952
Appl Immunohistochem Mol Morphol. 2006 Mar;14(1):83-7
16540736
Steroids. 2005 May-Jun;70(5-7):372-81
15862820
Endocr Rev. 2004 Dec;25(6):869-98
15583021
Mol Endocrinol. 2003 Feb;17(2):203-8
12554748
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
15761078
Curr Oncol Rep. 2004 Jul;6(4):259-67
15161576
Cancer Res. 2002 Apr 1;62(7):2141-50
11929836
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
Int J Cancer. 1996 Jul 29;67(3):357-64
8707409
Cancer Res. 2005 Sep 1;65(17):7568-72
16140919
Int J Cancer. 2006 Jan 15;118(2):257-62
16231326
Nat Med. 1999 Oct;5(10):1130-1
10502813
Arch Pathol Lab Med. 2000 Oct;124(10):1467-70
11035577
J Clin Oncol. 2009 Jan 20;27(3):411-7
19064969
Cancer Res. 2005 Feb 15;65(4):1459-70
15735034
Lancet Oncol. 2004 Mar;5(3):174-81
15003201
J Natl Cancer Inst. 2005 Mar 2;97(5):339-46
15741570
Mol Endocrinol. 2002 Jan;16(1):100-15
11773442
Cancer Res. 2005 Jul 15;65(14):6450-8
16024650
J Thorac Cardiovasc Surg. 2005 Oct;130(4):979-86
16214508
Nat Rev Cancer. 2007 Oct;7(10):778-90
17882278
Clin Cancer Res. 2005 Oct 15;11(20):7280-7
16243798